Clodronate-induced cell apoptosis in human thyroid carcinoma is mediated via the P2 receptor signaling pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 2, 2009, Pages 613-623

  Yang, De Ming ^a,b   Teng, Hsiao Chuan ^a   Chen, Kuan Hsuan ^a   Tsai, Ming Long ^a   Lee, Ting Kuei ^a   Chou, Yueh Ching ^a   Chi, Chin Wen ^a,b   Chiou, Shi Hwa ^a,b   Lee, Chen Hsen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 AMINOETHOXYDIPHENYLBORANE; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CASPASE 3; CISPLATIN; CLODRONIC ACID; CYCLIC AMP; LIPOCORTIN 5; PURINERGIC P2 RECEPTOR; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; DRUG MECHANISM; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; THYROID PAPILLARY CARCINOMA; XENOTRANSPLANTATION;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; CLODRONIC ACID; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 67651067953     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.152447     Document Type: Article

References (40)

1. Balogh J, Wihlborg AK, Isackson H, Joshi BV, Jacobson KA, Arner A, and Erlinge D (2005) Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. J Mol Cell Cardiol 39:223-230. (Pubitemid 40995011)
2. Brown JE, Neville-Webbe H, and Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11:207-224. (Pubitemid 38832826)
3. 2+ entry in living cells. Toxicol Appl Pharmacol 227:430-439.
4. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al. (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CG3-positive cells. PLoS ONE 3:e2637.
5. Coutinho-Silva R, Stahl L, Cheung KK, de Campos NE, de Oliveira Souza C, Ojcius DM, and Burnstock G (2005) P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol 288:G1024-G1035. (Pubitemid 40563146)
6. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, and Schuetz F (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up. Ann Oncol 19:2007-2011.
7. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363. (Pubitemid 28363797)
8. Dixon CJ, Hall JF, Webb TE, and Boarder MR (2004) Regulation of rat hepatocyte function by P2Y receptors: focus on control of glycogen phosphorylase and cyclic AMP by 2-methylthioadenosine 5′-diphosphate. J Pharmacol Exp Ther 311:334-341.
9. Elia MG, Muscella A, Greco S, Vilella S, Storelli C, and Marsigliante S (2003) Disturbances in purinergic [Ca2+]i signaling pathways in a transformed rat thyroid cell line. Cell Calcium 33:59-68. (Pubitemid 36221690)
10. Geran RI, Greenberg NH, Mac Donald MM, Schumacher AM, and Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:1-88.
11. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(3 Suppl):840-847.
12. Holmuhamedov E, Lewis L, Bienengraeber M, Holmuhamedova M, Jahangir A, and Terzic A (2002) Suppression of human tumor cell proliferation through mitochondrial targeting. FASEB J 16:1010-1016. (Pubitemid 34753507)
13. Huang SM, Lee CH, Chou FF, Liaw KY, and Wu TC (2005) Characteristics of thyroidectomy in Taiwan. J Formos Med Assoc 104:6-11.
14. Inoue K, Hosoi J, and Denda M (2007) Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. J Invest Dermatol 127:362-371. (Pubitemid 46106915)
15. Kondo T, Ezzat S, and Asa SL (2006) Pathogenetic mechanisms in thyroid follicularcell neoplasia. Nat Rev Cancer 6:292-306.
16. Kung SP, Lee CH, Yang AH, Chi CW, Tseng LM, and Wu CW (2006) Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin. J Chin Med Assoc 69:74-79.
17. Lee CH, Hsu LS, Chi CW, Chen GD, Yang AH, and Chen JY (1998) High frequency of rearrangement of the RET protooncogene (RET/PTC) in Chinese papillary thyroid carcinomas. J Clin Endocrinol Metab 83:1629-1632.
18. Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, and Hassinen IE (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255-1262. (Pubitemid 34441791)
19. Lin JD, Chao TC, Weng HF, Huang HS, and Ho YS (1996) Establishment of xenografts and cell lines from well-differentiated human thyroid carcinoma. J Surg Oncol 63:112-118. (Pubitemid 26357918)
20. Linford NJ, Schriner SE, and Rabinovitch PS (2006) Oxidative damage and aging: spotlight on mitochondria. Cancer Res 66:2497-2499.
21. Mamedova LK, Gao ZG, and Jacobson KA (2006) Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Biochem Pharmacol 72:1031-1041.
22. 2+]i via activation of ATP receptors in PC-Cl3 rat thyroid cell line. Cell Signal 14:61-67.
23. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, and Melendez-Zajgla J (2008) Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 27:48.
24. Martinez-Velazquez M, Melendez-Zajgla J, and Maldonado V (2007) Apoptosis induced by cAMP requires Smac/DIABLO transcriptional upregulation. Cell Signal 19:1212-1220. (Pubitemid 46561558)
25. Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, Auriola S, and Mönkkönen J (2008) Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19:391-399.
26. Muresan MM, Olivier P, Leclère J, Sirveaux F, Brunaud L, Klein M, Zarnegar R, and Weryha G (2008) Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 15:37-49.
27. Nagai T, Sawano A, Park ES, and Miyawaki A (2001) Circularly permuted green fluorescent proteins engineered to sense Ca2+. Proc Natl Acad Sci U S A 98:3197-3202. (Pubitemid 32220822)
28. 2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci U S A 101:17404-17409.
29. Peng CH, Chiou SH, Chen SJ, Chou YC, Ku HH, Cheng CK, Yen CJ, Tsai TH, Chang YL, and Kao CL (2008) Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol 18:128-140.
30. Schöfl C, Rössig L, Pötter E, von zur Mühlen A, and Brabant G (1995) Extracellular ATP and UTP increase cytosolic free calcium by activating a common P2u-receptor in single human thyrocytes. Biochem Biophys Res Commun 213:928-934.
31. 2+-signalling in human thyroid cancer cells. Mol Cell Endocrinol 133:33-39.
32. Shabbir M, Ryten M, Thompson C, Mikhailidis D, and Burnstock G (2008a) Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. BJU Int 101:352-359.
33. Shabbir M, Ryten M, Thompson C, Mikhailidis D, and Burnstock G (2008b) Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int 101:106-112. (Pubitemid 350233572)
34. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, et al. (2006) Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 66:4263-4272.
35. Vaughan KR, Stokes L, Prince LR, Marriott HM, Meis S, Kassack MU, Bingle CD, Sabroe I, Surprenant A, and Whyte MK (2007) Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. J Immunol 179:8544-8553.
36. White N and Burnstock G (2006) P2 receptors and cancer. Trends Pharmacol Sci 27:211-217.
37. White N, Ryten M, Clayton E, Butler P, and Burnstock G (2005) P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett 224:81-91. (Pubitemid 40720369)
38. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, et al. (1998) United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (Second Edition). Br J Cancer 77:1-10. (Pubitemid 28029765)
39. 2+ signaling of human thyroid carcinoma cell lines. Anticancer Res 24:1617-1623.
40. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, and Wu KJ (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:295-305.